Apellis Pharmaceuticals, Inc. (APLS) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Waltham, MA, United States. El CEO actual es Cedric Francois.
APLS tiene fecha de IPO 2017-11-09, 705 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $5.22B.
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic compounds that inhibit the complement system to treat autoimmune and inflammatory diseases. The company's lead product, pegcetacoplan, is in Phase III clinical trials for geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, with the approved product EMPAVELI addressing multiple rare hematologic, nephrologic, and neurologic indications. Apellis maintains a robust pipeline including APL-2006, a bispecific C3 and VEGF inhibitor, and APL-1030, a C3 inhibitor for neurodegenerative diseases, supported by strategic collaborations with Swedish Orphan Biovitrum AB and Beam Therapeutics. Founded in 2009 and headquartered in Waltham, Massachusetts, the company is advancing complement-inhibition science across multiple therapeutic areas with significant unmet medical needs.
